Bayer has secured an important regulatory advantage in a narrowly defined but increasingly competitive segment of precision lung cancer therapy. The United States Food and Drug Administration granted accelerated approval to HYRNUO, or sevabertinib, on September 9, 2026 for previously untreated adults with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumours carry HER2, or ERBB2, tyrosine kinase domain activating mutations. The decision moves the oral kinase inhibitor into the first-line setting after an earlier accelerated approval covered previously treated disease.
The approval is based on Cohort F of Bayer’s ongoing Phase 1/2 SOHO-01 study rather than a randomized Phase 3 trial. Among 69 treatment-naïve patients, the confirmed objective response rate was 75%, including complete responses in 6%, while 73% of responders maintained their response for at least six months and 38% remained in response for at least 12 months. Those results were strong enough for accelerated approval, but continued approval depends on confirmation of clinical benefit in the ongoing Phase 3 SOHO-02 trial.
Why does first-line HYRNUO matter more than another HER2 approval?
HER2-mutated lung cancer has historically occupied an awkward position in precision oncology. Targeted drugs transformed first-line treatment for tumours driven by EGFR, ALK, ROS1 and several other genomic alterations, yet HER2-mutated disease lagged behind despite being biologically identifiable. HER2 activating mutations occur in roughly 2% to 4% of non-small cell lung cancers, with many concentrated in the kinase domain, giving drug developers a relatively small but molecularly defined patient population.
Until recently, treatment options specific to HER2 mutations were largely concentrated after prior systemic therapy. AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu established an important targeted option, while Boehringer Ingelheim’s oral HER2 inhibitor zongertinib and Bayer’s sevabertinib subsequently entered the previously treated setting. Moving an oral targeted therapy to the front line changes the sequence because oncologists can potentially attack the driver mutation before exposing patients to conventional chemotherapy-based combinations.
That sequencing advantage is commercially meaningful as well as clinically relevant. A drug used earlier in metastatic disease generally has access to a broader eligible population and potentially longer treatment duration than one reserved for later lines, assuming tolerability and disease control remain favourable. Bayer therefore gains more than a label extension: it gains the opportunity to establish HYRNUO as part of the initial treatment conversation for newly diagnosed HER2-mutant advanced disease.
Is a 75% response rate enough to establish HYRNUO as the preferred treatment?
The 75% response rate is compelling, but cross-trial comparisons immediately complicate the story. Boehringer Ingelheim’s zongertinib produced a confirmed response rate of 76% in 74 previously untreated patients with HER2-mutated advanced non-small cell lung cancer, with median progression-free survival of 14.4 months and median duration of response of 15.2 months in published Beamion LUNG-1 data. Zongertinib also demonstrated intracranial activity, with a 47% confirmed intracranial response rate in a separate cohort containing patients with active brain metastases.
Those figures cannot be treated as a head-to-head comparison because the trials differ in populations, follow-up and design. They do, however, demonstrate that Bayer is not entering an empty market where any strong response rate automatically establishes leadership. Sevabertinib and zongertinib are increasingly being evaluated side by side in clinical discussions because both are orally administered HER2-selective tyrosine kinase inhibitors and both are moving through confirmatory first-line development.
The American Society of Clinical Oncology’s living guideline already reflects that changing landscape. Its 2026 update discusses sevabertinib, zongertinib and trastuzumab deruxtecan among targeted options for HER2 activating mutations and notes the importance of ongoing randomized trials in determining how these therapies ultimately fit into first-line care. The evidence quality remains limited partly because much of the current efficacy database comes from relatively small single-arm cohorts.
Could oral dosing become a meaningful competitive advantage?
Convenience is not trivial in metastatic cancer treatment. HYRNUO and zongertinib are oral small-molecule therapies, whereas Enhertu is administered intravenously, meaning treatment choice can influence infusion-centre use, patient travel and ongoing healthcare-system workload. Oral administration alone cannot compensate for inferior efficacy or safety, but comparable clinical benefit could make route of administration an important differentiator.
Safety will therefore matter considerably. Bayer reported diarrhoea, rash, stomatitis, paronychia, nausea and weight loss among the most common adverse reactions in the broader SOHO-01 safety population. Physicians will compare not merely response rates but the frequency of dose interruptions, reductions, serious toxicities and treatment discontinuations when choosing between long-term therapies.
The same competitive calculation applies to zongertinib. Published first-line data reported treatment-related adverse events in 91% of patients, but grade 3 or higher treatment-related events occurred in 19%, and the investigators characterized most treatment-related toxicity as low grade. As randomized data mature, differences in tolerability may become as commercially important as relatively small differences in tumour response.
Why does accelerated approval leave an important question unresolved?
Accelerated approval allows the FDA to make promising treatments available earlier based on surrogate or intermediate endpoints reasonably likely to predict clinical benefit. In oncology, objective response rate and duration of response frequently support that pathway when patient need is high and randomized survival data are not yet complete. The trade-off is that sponsors must subsequently verify the treatment’s benefit.
For HYRNUO, that responsibility sits with SOHO-02. The randomized Phase 3 study is comparing sevabertinib with standard treatment in previously untreated advanced HER2-mutated non-small cell lung cancer, and the FDA lists completion of that trial as the post-marketing requirement supporting the accelerated approval. The agency’s accelerated-approval database currently gives a projected completion date in 2029.
That timeline means Bayer can commercialize into the first-line setting years before the definitive randomized answer is available. Early adoption could create familiarity among oncologists and generate valuable real-world experience, but it also leaves open whether the large response rate ultimately converts into superior progression-free survival, durable clinical benefit and potentially improved survival against an active standard-of-care comparator.
How could brain metastases influence the HYRNUO-zongertinib contest?
Central nervous system activity can become a major differentiator in lung cancer because brain metastases are common during the course of advanced disease. Targeted agents that penetrate the central nervous system effectively can reduce reliance on local interventions and potentially delay intracranial progression.
Zongertinib has already generated specific prospective evidence in patients with active brain metastases, including the 47% intracranial response reported in Beamion LUNG-1. That does not prove superiority over HYRNUO, but it provides oncologists with a concrete dataset when considering patients whose disease has spread to the brain.
Bayer will therefore need the broader sevabertinib programme to establish how reliably the drug controls both systemic and intracranial disease. In precision lung cancer, successful drugs increasingly need to demonstrate efficacy across anatomical compartments rather than simply shrink extracranial tumours.
Could testing become the gatekeeper to commercial uptake?
HYRNUO’s label requires identification of an eligible HER2 activating mutation using an FDA-authorized test. That makes molecular testing infrastructure part of the commercial pathway because patients cannot receive a genotype-specific drug if clinicians do not identify the mutation before choosing therapy.
This creates a wider implication for diagnostic laboratories and next-generation sequencing providers. As more uncommon molecular subgroups receive front-line targeted options, comprehensive genomic testing at diagnosis becomes increasingly valuable. A fragmented testing approach focused only on the most common driver alterations risks missing patients eligible for emerging targeted therapies.
For Bayer and competitors, therefore, market growth depends partly on diagnostic behaviour outside their direct control. The more routinely HER2 activating mutations are identified before treatment starts, the larger the addressable first-line population becomes.
What would establish Bayer as the long-term leader?
The first milestone is execution of the accelerated-approval launch. Bayer needs oncologists to become comfortable selecting HYRNUO early, managing its adverse effects and integrating mutation testing quickly enough that treatment decisions are not delayed.
The more consequential milestone is SOHO-02. A successful randomized study would convert the current response-rate story into stronger comparative evidence and could secure traditional approval. Failure would make the current first-line position substantially more vulnerable, particularly if competing Phase 3 programmes establish stronger progression-free-survival or survival results.
Bayer has therefore won an important regulatory race, but it has not settled the competitive one. HYRNUO’s 75% first-line response rate is strong enough to change immediate treatment options for HER2-mutant lung cancer, yet zongertinib’s emerging data show how quickly a narrow targeted market can become crowded. The eventual winner may be determined less by who reached the label first than by which drug produces the clearest combination of durability, brain activity, tolerability and randomized clinical benefit.
